AACR 2020 -- Tumor models can be generally divided into immunologically 'cold' and 'warm' categories based on their immune cell infiltrates and their ability to respond to checkpoint inhibition. 'Warm' tumors respond well to immuno-therapies while 'cold' tumors do not. Researchers are searching for ways to make 'cold' tumors more responsive.
AACR 2020 -- Informed selection of syngeneic models for use in preclinical drug development is critical for success. CT26 colorectal and 4T1-Luc breast tumors were treated with anti-mCTLA-4 to address how the tumor microenvironment influences therapeutic outcome.
AACR 2020 -- Hepatocellular carcinoma (HCC) is the third leading cause of cancer related deaths and is refractory to standard chemo and radiation therapies.
AACR 2020 -- The degree of methylation in the promoter region of the O-6-methylguanine-DNA methyltransferase (MGMT) gene is widely accepted as a prognostic biomarker of patient outcomes in Glioblastoma multiforme (GBM).
AACR 2020 -- The continual pressure to develop molecules that target the immune system requires that there are new, reliable and well-characterized preclinical models available.
AACR 2020 -- The complex and dynamic nature of the tumor-immune microenvironment (TME) presents challenges for identification of robust and predictive biomarkers in immuno-oncology (IO).
AACR 2020 -- Breast cancer is generally regarded as an immunologically "cold" cancer, often with minimal tumor CD8+ T cell infiltrate and low immunogenicity.
Congratulations! You've just selected the contract research organization (CRO) that best fits your goals, timeline, budget and philosophy. You're confident that the project team, study and company will be successful! What's next?
A virtual biotech company chose Covance to conduct two Phase III clinical trials for a new antibiotic treating life-threatening skin infections, such as methicillin-resistant staphylococcus aureus (MRSA).
A top-5 pharmaceutical company partnered with us to provide field reimbursement management (FRM) services for their autoimmune infusion therapy program. Learn more about how we played a critical role in facilitating enrollment and stakeholder satisfaction.
